Cyngn Inc. — Q1 2024 Form 10-Q Summary
Business context and reporting period
Cyngn develops autonomous-vehicle technology for industrial applications, including its DriveMod software, Enterprise Autonomy Suite, fleet-management tools and related hardware. The filing covers the unaudited three months ended March 31, 2024, compared with the three months ended March 31, 2023.
Financial performance and liquidity
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Revenue | $5,513 | $872,800 |
| Cost of revenue | $113,776 | $616,694 |
| Research and development | $3.15 million | $3.03 million |
| General and administrative | $2.70 million | $3.07 million |
| Loss from operations | $(5.97) million | $(5.84) million |
| Net loss | $(5.97) million | $(5.63) million |
| Basic and diluted loss per share | $(0.08) | $(0.15) |
| Net cash used in operating activities | $(5.84) million | $(5.38) million |
- Revenue consisted primarily of $2,727 of subscription revenue and $2,786 of hardware revenue; NRE revenue declined to zero from $870,000.
- Gross loss was approximately $108,000. Revenue was insufficient to cover cost of revenue and operating expenses, producing a substantially negative operating margin.
- Cash was $2.19 million and short-term U.S. Treasury investments were $2.58 million at March 31, 2024, versus $3.59 million and $4.56 million, respectively, at December 31, 2023.
- Total current assets were $6.27 million and total liabilities were $1.82 million. The filing reports no conventional debt; operating lease liabilities totaled $852,226, with the office lease expiring in May 2025.
- Investing activities provided $1.79 million, primarily because maturities of short-term investments exceeded purchases. Financing activities provided $2.65 million from equity financing.
- Accumulated deficit increased to $165.99 million from $160.02 million at year-end 2023. Stockholders’ equity declined to $7.97 million.
Material changes versus the prior comparable period
- Revenue fell by approximately 99% year over year, principally because Q1 2023 included $870,000 of NRE revenue while Q1 2024 did not.
- Net loss increased by approximately $341,000, despite lower total operating expenses, because the revenue decline more than offset the reduction in general and administrative expense.
- Research and development expense increased approximately 3% to $3.15 million, while general and administrative expense decreased approximately 13% to $2.70 million.
- Operating cash usage increased approximately 8% to $5.84 million.
- The weighted-average share count increased to 77.1 million from 37.7 million, and shares outstanding at March 31, 2024 were 88.5 million versus 64.8 million at December 31, 2023, reflecting substantial equity issuance and dilution.
- The Company recorded a $52,723 impairment charge for expired international patent assets. It had abandoned certain intellectual-property rights and related inventory in 2023.
Outlook, risks and unusual items
- Management states that the Company has substantial doubt about its ability to continue as a going concern for the 12 months following issuance of the financial statements. Management expects to rely primarily on additional equity and/or debt financing, revenue growth and cost controls.
- The filing provides no quantified revenue or earnings guidance. Management targets scaled deployments beginning in the second half of 2024 and expects annual R&D expense to exceed 2023 levels.
- As of March 31, 2024, the Company had insufficient funds for sustainable operations without additional funding, and management acknowledges that financing plans may not succeed on acceptable terms, or at all.
- Nasdaq granted an additional 180-day extension on February 21, 2024, giving the Company until August 19, 2024 to regain compliance with the $1.00 minimum bid-price requirement.
- After quarter-end, the Company sold an additional 931,910 shares under its ATM program for net proceeds of $141,320. It also completed a public offering of 50 million shares and pre-funded warrants, followed by 2.04 million additional shares from the underwriter’s over-allotment option, generating approximately $5.2 million of gross proceeds before approximately $0.6 million of offering costs.
- The filing identifies risks related to continued losses, limited recurring revenue, dependence on capital markets, dilution, execution of commercial deployments, inflation, interest rates, geopolitical events, supply-chain disruption and Nasdaq listing compliance.
- Management reported that disclosure controls and procedures were effective as of March 31, 2024, with no material change in internal control over financial reporting.
Important facts for investors to verify
- Whether the post-quarter-end offerings and ATM proceeds provide sufficient liquidity to fund operations for the next 12 months.
- The timing, scale and economics of the planned second-half 2024 deployments and whether they convert into recurring EAS subscription revenue.
- The Company’s ability to reduce its approximately $5.8 million quarterly operating cash burn while continuing planned R&D investment.
- Progress toward Nasdaq’s August 19, 2024 minimum bid-price compliance deadline.
- The extent of future dilution from additional equity issuance, approximately 7.24 million outstanding warrants and approximately 17.1 million outstanding stock options.
- The filing contains an apparent inconsistency in ATM activity disclosures: the stockholders’ equity and cash-flow information reflects approximately $2.65 million of net proceeds and 13.3 million shares issued in the quarter, while Note 7 and MD&A state 17.0 million shares and $4.46 million of cumulative net proceeds as of March 31, 2024. Investors should reconcile this difference against the filed financial statements and offering records.